Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of gemcitabine + nab-paclitaxel + dexamethasone for recurrent/refractory peripheral T-cell lymphoma
ChiCTR1800018710Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel and dexamethasone in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: objective response rate. Started Oct 2018; status: recruiting.
02
Drugs
gemcitabinepaclitaxeldexamethasone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR1800018710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018710.